NOT KNOWN DETAILS ABOUT BRD4 INHIBITION BY ABBV-744 IN CANCER RESEARCH STUDIES

In Section C, contributors will get ABBV-744 and oral navitoclax. In Phase D, individuals will get ABBV-744 and ruxolitinib. Participants will obtain treatment right until disorder progression or the individuals are unable to tolerate the study drugs.Doable new methods for your analysis and treatment of AML. (A) The identification of super enhancer